BETTERLIFE PHARMA INC - BETRF STOCK NEWS

BetterLife Pharma Inc. announces progress in its IND-enabling studies for BETR-001, a non-hallucinogenic LSD derivative for mental disorders. The company has initiated GLP studies for metabolism and genotoxicity. BETR-001 has shown robust activity in animal models without hallucinogenic effects. BetterLife plans to file the IND application with the FDA by the end of 2024.

In March 2024, BetterLife disclosed its intention to conduct private placement offerings of Convertible Debentures to fund the development of BETR-001. The company closed a tranche of $30,000 10% Convertible Debentures with a two-year maturity to further advance BETR-001 development. Each Convertible Debenture is convertible into units of the company, including one common share and one share purchase warrant.

BetterLife Pharma Inc. (BETRF) will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference, showcasing their focus on mental disorder treatments. The event will feature key executives discussing the company's initiatives and engaging with potential investors.

BetterLife Pharma Inc. announces participation in Bloom Burton Healthcare Investor Conference and resolution of a claim by issuing common shares valued at $19,687.50.

BetterLife Pharma Inc. closes $1.168 million convertible debentures to advance BETR-001 development, a non-hallucinogenic derivative of LSD, targeting anxiety and depression disorders. FDA's breakthrough therapy designation for LSD in anxiety disorders validates BetterLife's research efforts. BETR-001 shows promising preclinical data with improved safety profile over LSD. Dr. Doroudian and Dr. Sangha, insiders of the company, subscribed for $100,000 each in the private placement.

BetterLife Pharma Inc. announces the development of 2-bromo-LSD for treating depression, with BETR-001 entering human trials in 2024. The company closes $65,000 in convertible debentures and plans further private placements for advancing BETR-001 and general working capital.

BetterLife Pharma Inc. (BETR) closes $300,000 convertible debentures to advance development of BETR-001, a non-hallucinogenic derivative of LSD, for mental disorders treatment.

BetterLife Pharma Inc. (BETR) has closed a non-brokered private placement, issuing 2,000,000 units at $0.10 per unit, generating $200,000 in gross proceeds. Each unit includes one common share and one warrant, with Dr. Ahmad Doroudian, the CEO, subscribing for 1,000,000 units. The private placement is exempt from certain regulatory requirements due to the company not being listed on a specified stock exchange.

BetterLife Pharma Inc. (BETR) extends the expiry date of 6,386,298 outstanding share purchase warrants to December 2, 2025, with an original exercise price of $0.60. The warrants were granted pursuant to the exercise of the Company’s December 2020 private placement offering of special warrants. Previously issued warrant certificates remain valid and enforceable until the amended expiry date. Warrantholders may exercise their warrants by following the specified procedure.

BetterLife Pharma Inc. (BETR) announces the publication of its patent application for BETR-001 and LSD derivatives by the US Patent and Trademark Office. The application covers the development of non-hallucinogenic derivatives of LSD for the treatment of neuropsychiatric and neurological conditions, including depression, anxiety, cluster headaches, and neuropathic pain. The company's efforts in developing novel therapies for mental disorders were also recognized in The Atlantic, highlighting the potential of the BETR-001 program. BETR-001 is projected to enter human trials in 2024.